Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Metastatic CRC: Moving Into the Future

October 22nd 2018

Precision Medicine Further Explored in Metastatic CRC

October 22nd 2018

Immunotherapy in MSS Colorectal Cancer

October 22nd 2018

Immunotherapy Regimens in dMMR/MSI-High Metastatic CRC

October 22nd 2018

Significance of MSI Status and TMB in Metastatic CRC

October 22nd 2018

Triplet Regimens in BRAF-Mutant Metastatic CRC

October 22nd 2018

Targeting BRAF in Metastatic CRC

October 22nd 2018

Tumor Sidedness in CRC: Distinguishing Factors

October 22nd 2018

Combination Strategies in Frontline Metastatic CRC

October 22nd 2018

RAS Status and Treatment Decisions in Metastatic CRC

October 22nd 2018

Recommendations for Molecular Testing in Metastatic CRC

October 22nd 2018

Current State of Molecular Testing for Metastatic CRC

October 22nd 2018

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Lenz Highlights Ongoing Advances in mCRC

October 17th 2018

Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.

Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

October 16th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).

Dr. Lenz on the Changing Landscape of Metastatic Colorectal Cancer

October 16th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).

ESMO Asia mCRC Guidelines: Insights on Impact and Uptake

October 12th 2018

Dr. McCollum on Maintenance Therapy for Metastatic CRC

October 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses maintenance therapy for patients with metastatic colorectal cancer.

Dr. Becerra Discusses Dosing Strategies in CRC

October 5th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.

Later Lines of Therapy for Metastatic Colorectal Cancer

September 28th 2018